# Safety of Somatropin and Induction of Puberty With 17-beta-oestradiol in Girls With Turner Syndrome

> **NCT01518062** · PHASE4 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 65 (actual)

## Conditions studied

- Genetic Disorder
- Turner Syndrome

## Interventions

- **DRUG:** somatropin
- **DRUG:** somatropin
- **DRUG:** somatropin
- **DRUG:** oestrogen

## Key facts

- **NCT ID:** NCT01518062
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1989-11
- **Primary completion:** 2003-09
- **Final completion:** 2003-09
- **Target enrollment:** 65 (ACTUAL)
- **Last updated:** 2017-01-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01518062

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01518062, "Safety of Somatropin and Induction of Puberty With 17-beta-oestradiol in Girls With Turner Syndrome". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01518062. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*